Rasheed Mazen Abdalla, Ballotin Vinícius Remus, Bigarella Lucas Goldmann, Soldera Jonathan
Acute Medicine, University of South Wales, Cardiff CF37 1DL, United Kingdom.
School of Medicine, Universidade de Caxias do Sul, Caxias do Sul 95070-560, Brazil.
World J Methodol. 2023 Sep 20;13(4):296-322. doi: 10.5662/wjm.v13.i4.296.
The coronavirus disease 2019 (COVID-19) pandemic has had a profound impact on global health, primarily characterized by severe respiratory illness. However, emerging evidence suggests that COVID-19 can also lead to secondary sclerosing cholangitis (SC), referred to as post-COVID-19 cholangiopathy.
To synthesize currently reported cases to assess the current state of knowledge on post-COVID-19 cholangiopathy.
Medical Subject Headings and Health Sciences Descriptors were used to retrieve relevant studies, which were combined using Boolean operators. Searches were conducted on electronic databases including Scopus, Web of Science, and MEDLINE (PubMed). Studies published in English, Spanish, or Portuguese were included, with no restrictions on the publication date. Additionally, the reference lists of retrieved studies were manually searched. Simple descriptive analyses were used to summarize the results. Then the data were extracted and assessed based on Reference Citation Analysis (https://www.referencecitationanalysis.com/).
The initial search yielded a total of 192 articles. After screening, 85 articles were excluded due to duplication, leaving 107 articles for further review. Of these, 63 full-length articles met the inclusion criteria and were included in the analyses. Most of the patients were male and exhibited elevated liver function tests (93.8%). Magnetic resonance imaging revealed duct thickening with contrast enhancement (47.7%), as well as beading of the intrahepatic ducts (45.7%) with peribiliary contrast enhancement on diffusion (28.7%). Liver biopsy results confirmed SC in most cases (74.4%). Sixteen patients underwent liver transplantation, with three experiencing successful outcomes.
Post-COVID-19 cholangiopathy is a serious condition that is expected to become increasingly concerning in the coming years, particularly considering long COVID syndromes. Although liver transplantation has been proposed as a potential treatment option, more research is necessary to establish its efficacy and explore other potential treatments.
2019年冠状病毒病(COVID-19)大流行对全球健康产生了深远影响,主要表现为严重的呼吸道疾病。然而,新出现的证据表明,COVID-19也可导致继发性硬化性胆管炎(SC),即COVID-19后胆管病。
综合目前报告的病例,评估关于COVID-19后胆管病的现有知识状况。
使用医学主题词和健康科学描述符检索相关研究,并使用布尔运算符进行合并。在包括Scopus、科学网和MEDLINE(PubMed)在内的电子数据库中进行检索。纳入以英文、西班牙文或葡萄牙文发表的研究,对发表日期无限制。此外,还手动检索了检索到的研究的参考文献列表。使用简单的描述性分析来总结结果。然后根据参考文献引用分析(https://www.referencecitationanalysis.com/)对数据进行提取和评估。
初步检索共获得192篇文章。筛选后,85篇文章因重复被排除,剩下107篇文章进行进一步审查。其中,63篇全文符合纳入标准并纳入分析。大多数患者为男性,肝功能检查结果升高(93.8%)。磁共振成像显示胆管增厚并伴有对比增强(47.7%),以及肝内胆管串珠样改变(45.7%),扩散加权成像上胆管周围对比增强(28.7%)。肝活检结果在大多数病例中证实为SC(74.4%))。16例患者接受了肝移植,3例获得成功。
COVID-19后胆管病是一种严重疾病,预计在未来几年会越来越受到关注,尤其是考虑到长期COVID综合征。虽然肝移植已被提议作为一种潜在的治疗选择,但需要更多研究来确定其疗效并探索其他潜在治疗方法。